OnBioVC continues to illuminate a deeply concerning financing trend observed over the last several years of aggregated data; one may term the resultant effect of this discernable development as an erosion in U.S.-based biomedical innovation. The metric invoked to quantify such bold nomenclature is simply the decline in first-time, Series A, institutional financings. With fewer [...]